BeNeLuxBelgiumNetherlandsLuxembourg

Fluorescent tumours in the clinic

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted dyes in patients. Now for the first time, a Dutch-German team of researchers has found a way to convince regulatory authorities that their fluorochromes are safe and can be tested on human subjects. In November, the team got the go-ahead for a Phase I study in breast cancer patients with the fluorochrome IR dye 800 CW (LI-COR Bioscience) coupled to the antibody drug Avastin (Roche).
“Our advantage is that we already have a lot of clinical data about the safety and biodistribution of the cancer therapeutic Avastin, which binds to VEGF produced by cancer cells,” said Werner Scheuer from Pharma Research & Early Development at Roche (Penzberg), who developed the anti­body-flurochrome conjugates in cooperation with Vasilis Ntziachristos (TU Munich) and Go van Dam (Medical College Groningen). In the November issue of the Journal of Nuclear Medicine (52(11): 1778-1785), the authors provided evidence that their cancer imaging agent behaves in animals as Avastin does in humans. For proving safety in humans, they will use microdoses of the dye – 100 times lower than the lowest dose in which the cancer drug shows an effect. “We want to statistically prove that breast cancer patients benefit from image-guided surgery with targeted fluorochromes,” explains Ntziachristos. He has developed a camera system that can identify the tumour margins with seven times better resolution than a surgeon can with the naked eye. A pipeline of antibody-fluorochrome conjugates is already being tested in animals.

BeNeLuxBelgiumNetherlandsLuxembourg

22.11.2007

Ghent – Novartis and Innogenetics have settled a patent litigation suit, giving Innogenetics non-exclusive rights to continue to develop and commercialize HCV immunodiagnostics in undisclosed European countries. Chiron Corp., now...

BeNeLuxBelgiumNetherlandsLuxembourg

22.11.2007

Leiden – Pharming has raised a70 million in a private placement of convertible bonds due in 2012. The company will buy back royalty rights to future revenues from four Pharming products, thereby ending a 2006 deal with Paul...

BeNeLuxBelgiumNetherlandsLuxembourg

22.11.2007

Liege – Molecular diagnostics com-pany Oncomethylome Sciences (Belgium) has increased its capital with the sup­port of “institutional and qualified investors”. The volume of the placing for the gene methylation specialist was...

BeNeLuxBelgiumNetherlandsLuxembourg

22.11.2007

Leiden – The results from Crucell N.V.’s phase I study with a monoclonal antibody cocktail against rabies suggest that the product candidate was well tolerated by the patients, in dose escalation as well as in combination with...

BeNeLuxBelgiumNetherlandsLuxembourg

20.11.2007

Leuven – Integrated DNA Technologies, the largest US supplier of custom oligonucleotides, will expand its services in Europe and is to open a new production facility at its European daughter company IDT BVBA in Belgium. IDT’s...

BeNeLux, FinlandBelgiumNetherlandsLuxembourg

04.10.2007

Kuipio/Helsinki – Two Finnish biotech companies have succeed in attracting investments of several million euros. Brain diagnostics firm Nexstim Ltd, whichbased in Helsinki, has announced an €8 million financing round with LSP...

BeNeLuxBelgiumNetherlandsLuxembourg

26.09.2007

Ghent - Hepatocellular carcinoma is very difficult to detect, and it is a major cause of death in Asia and Africa, with rising incidence in Western countries. Now, researchers under Liesbeth Desmyter at the VIB, Flanders...

Germany, BeNeLuxBelgiumNetherlandsLuxembourg

24.09.2007

Ghent – Boehringer Ingelheim and Ablynx NV have extended their large research and development deal. In January, the Belgian biopharmaceutical company and the German pharma firm signed an exclusive global collaboration potentially...

BeNeLuxBelgiumNetherlandsLuxembourg

24.09.2007

Amsterdam – Agendia BV has raised €25 million in a fourth financing round. ING, one of the largest bank insurers, becomes a shareholder of Agendia, a molecular diagnostics company that develops and provides highly specific cancer...

BeNeLuxBelgiumNetherlandsLuxembourg

24.09.2007

Brussels – The 386 laboratories in Belgium licensed to carry out biomedical experiments involving animals used 756,715 animals last year, which is a slight increase from the previous year. Federal public authorities note that 92%...

Displaying results 181 to 190 out of 304

< Previous 181-190 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/18/article/fluorescent-tumours-in-the-clinic.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • EPIGENOMICS4.34 EUR11.57%
  • PAION2.86 EUR10.85%
  • STRATEC BIOMEDICAL41.92 EUR3.92%

FLOP

  • CYTOS0.15 CHF-6.25%
  • MAGFORCE5.40 EUR-6.09%
  • CO.DON2.70 EUR-5.26%

TOP

  • BIOFRONTERA2.84 EUR29.1%
  • EPIGENOMICS4.34 EUR13.3%
  • VITA 344.42 EUR7.5%

FLOP

  • MAGFORCE5.40 EUR-21.7%
  • CYTOS0.15 CHF-16.7%
  • CO.DON2.70 EUR-14.0%

TOP

  • SANTHERA89.00 CHF2260.7%
  • CO.DON2.70 EUR181.3%
  • PAION2.86 EUR125.2%

FLOP

  • CYTOS0.15 CHF-96.1%
  • THERAMETRICS0.07 CHF-50.0%
  • 4SC0.94 EUR-44.4%

No liability assumed, Date: 29.10.2014


Current issue

All issues

Product of the week

Products